<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03243526</url>
  </required_header>
  <id_info>
    <org_study_id>N-42-2017</org_study_id>
    <nct_id>NCT03243526</nct_id>
  </id_info>
  <brief_title>Effect of Fluid Management Guided by Pulse Pressure Variation Vs Central Venous Pressure on Lung Water Assessed by Lung Ultrasound During Liver Transplantation</brief_title>
  <official_title>The Effect of Fluid Management Guided by Pulse Pressure Variation Versus Central Venous Pressure on Extra Vascular Lung Water Assessed by Lung Ultrasound Score During Liver Transplantation. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim in this study to assess the effect of fluid management in patient undergoing
      orthotopic liver transplantation either by using pulse pressure variation or by central
      venous pressure. we will assess the impact of fluid management by either methods on
      oxygenation and extra vascular lung water visualized by lung ultrasound.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After induction of anesthesia lung ultrasound will be performed and arterial blood gases
      (ABG) will be taken.

      All patients in both groups will receive maintenance fluid in the form of crystalloids
      (ringer acetate) 4 ml/kg/H. Then fluid boluses will be given according to each group:

      Group c (cvp): will receive 250 ml albumin 5% boluses to maintain CVP around 5 cmH2o Group P
      (ppv): will receive 250 ml albumin 5% boluses to maintain PPV below 13% as detected from
      invasive blood pressure monitor.

      For all patients in both groups: blood transfusion will be indicated with decreased HB% level
      below 7 mg/dl in arterial blood gases. Other blood product (FFP, platelets and
      cryoprecipitate) transfusion will be guided by lab results and clinical status of patient.
      Plasma will be transfused if INR &gt; 1.5 and platelets will be transfused if count &lt; 50, 000

      Lung ultrasound will be performed to diagnose EVLW. A Philips C5 ultrasound system (frequency
      5Hz; Philips Medical Systems, Suresnes, France) with an ordinary echo probe will be used.
      Chest ultrasound will be performed using the 12 regions method. Intercostals spaces on each
      side will be examined anteriorly (midclavicular line), laterally (anterior axillary line) and
      posteriorly (posterior axillary line) Four ultrasound aeration patterns a. Normal aeration
      (N): 0 score ; line sliding sign associated with respiratory movement or less than 3 B lines
      ; b. Moderate loss of lung aeration: score 1 ; a clear number of multiple visible B-lines
      with horizontal spacing between adjacent B lines ≤ 7 mm (B7 lines) c. Severe loss of lung
      aeration: score 2; multiple B lines fused together that were difficult to count with
      horizontal spacing between adjacent B lines ≤ 3 mm (B3 lines); and d. Pulmonary
      consolidation: score 3; hyperechoic lung tissue, accompanied by dynamic air bronchogram.

      The final LUS of the patient was the sum of each regional ultrasound score (ranging from 0 to
      36).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two groups one recieve fluid guided by CVP and othe by PPV</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>patient will be blinded and person who will do lung ultrasound</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>lung ultrasound score</measure>
    <time_frame>5 minutes after surgical wound closure</time_frame>
    <description>lung score assessed by lung ultrasound to assess lung water. score range from 0 to 36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung ultrasound score</measure>
    <time_frame>baseline 10 minutes after induction. and 1 hour after Intensive care admission</time_frame>
    <description>lung score assessed by lung ultrasound to assess lung water. score range from 0 to 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P/F ratio</measure>
    <time_frame>baseline 10 min after induction, 5 minutes after surgical wound closure and 1 hour after intensive care admission</time_frame>
    <description>ratio of Po2 to fraction of inspired oxygen.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung; Congestive</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Central venous pressure group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>fluid therapy to maintain CVP not 5 cmH2o</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulse pressure variation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluid therapy will be guided by PPV to be less than 14%</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluid therapy</intervention_name>
    <description>fluid resuscitation guided by CVP or PPV</description>
    <arm_group_label>Central venous pressure group</arm_group_label>
    <arm_group_label>Pulse pressure variation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASA physical status II- IV

          2. Child C (end stage liver disease) ESLD patient.

          3. Age (18- 70) years

          4. Patients undergoing orthotopic liver transplantation.

        Exclusion Criteria:

          1. Parents' refusal.

          2. Patients with chronic pulmonary disease ( Asthma, obstructive lung disease or
             restrictive lung diseases)

          3. Patient with impaired diastolic function more than grade I.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed Elayashy Mohamed Ahmed Hassan, M.D00</last_name>
    <phone>00201001833155</phone>
    <email>mohamedelayashy@kasralainy.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>amr hussien sayed, M.D</last_name>
    <phone>00201223657694</phone>
    <email>AmrHussein1981@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy Hospital , Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed elayashy mohamed ahmed hassan, M.D</last_name>
      <phone>00201001833155</phone>
      <email>mohamedelayashy@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology. 2000 Oct;32(4 Pt 1):859-65. Review.</citation>
    <PMID>11003635</PMID>
  </reference>
  <reference>
    <citation>Bozbas SS, Eyuboglu FO, Ozturk Ergur F, Gullu Arslan N, Sevmis S, Karakayali H, Haberal M. Pulmonary complications and mortality after liver transplant. Exp Clin Transplant. 2008 Dec;6(4):264-70.</citation>
    <PMID>19338487</PMID>
  </reference>
  <reference>
    <citation>Gardelli G, Feletti F, Nanni A, Mughetti M, Piraccini A, Zompatori M. Chest ultrasonography in the ICU. Respir Care. 2012 May;57(5):773-81. doi: 10.4187/respcare.01743. Review.</citation>
    <PMID>22546298</PMID>
  </reference>
  <reference>
    <citation>Aghdashi M, Broofeh B, Mohammadi A. Diagnostic performances of high resolution trans-thoracic lung ultrasonography in pulmonary alveoli-interstitial involvement of rheumatoid lung disease. Int J Clin Exp Med. 2013 Aug 1;6(7):562-6. Print 2013.</citation>
    <PMID>23936595</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>August 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Mohamed Elayashy Mohamed Ahmed Hassan</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

